Cohort Study of the Clinical Course of Macular Diseases in Japanese
NCT ID: NCT02081339
Last Updated: 2016-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2014-03-31
2024-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients with such macular diseases are registered and and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cohort Study of the Clinical Course of Macular Diseases in Kagawa
NCT02321267
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
NCT02181517
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
NCT02181504
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
NCT00150202
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
NCT03128463
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Macular diseases
ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
ranibizumab, aflibercept, pegaptanib, verteporphin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ranibizumab, aflibercept, pegaptanib, verteporphin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are agreed with the participation of this study.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyoto University, Graduate School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nagahisa Yoshimura
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nagahisa Yoshimura, MD
Role: STUDY_CHAIR
Kyoto University, Graduate School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kyoto University Graduate School of Medicine
Kyoto, Kyoto, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E2038
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.